GB2102 / Edding Genor Group - LARVOL DELTA

Development of GB2102, a novel and highly differentiated anti-FGFR2b antibody for the treatment of gastric cancer (AACR 2022) - "Bemarituzumab is an afucosylated humanized monoclonal antibody that specifically inhibits FGFR2b. In summary, preclinical studies showed that GB2102 is an anti-FGFR2b antibody with potent ADCC effect and strong FGF7 blocking but weak FGF10 inhibition. These results suggest that GB2102 is potentially a safe and effective candidate for the treatment of FGFR2b positive gastric cancer."

Late-breaking abstract • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • FGF10 • FGFR2